Real Headline from PR Newswire PR Newswire
“Novartis announces five-year data that reinforce the safety and efficacy profile of AimovigĀ® (erenumab-aooe) in adult patients with episodic migraine”
October 3, 2020
Read Article Smash PR Newswire Smashes From PR Newswire

Smashes of This Headline

1
Vote
Samsung Galaxy Black Friday Was a Tribute to Our Safety and Efficacy Profile of AimovigĀ® (Erenumab-Aooe) in Adult Patients With Episodic Migraine